Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited)
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million.